Skip to content

Ensemble, founded in 2003, was a biopharmaceutical company developing a novel class of therapeutics, called Ensemblins™, with a uniquely expansive macrocyclic structure. The company’s aim was to open up new ways to treat diseases by addressing drug targets considered inaccessible with conventional small molecule drugs. Ensemble ceased operations in 2017.

Latest News from Ensemble Therapeutics